Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
The advent of targeted therapy for treatment of human cancers has added significantly to our armamentarium as we strive to prolong patient survival while minimizing toxicity. In cancers driven by a dominant oncogene, targeted therapies have led to remarkable improvements in response and survival, wh...
Saved in:
Published in | Clinical cancer research Vol. 15; no. 24; pp. 7471 - 7478 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.12.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The advent of targeted therapy for treatment of human cancers has added significantly to our armamentarium as we strive to
prolong patient survival while minimizing toxicity. In cancers driven by a dominant oncogene, targeted therapies have led
to remarkable improvements in response and survival, whereas in others the outcome has been more modest. One key aspect toward
realizing the potential of targeted therapies is a better understanding of the intrinsic or acquired resistance mechanisms
that limit their efficacy. The articles in this CCR Focus provide insights into molecular mechanisms of resistance to targeted therapy. Recent discoveries of the molecular pathways
that mediate intrinsic resistance to targeted therapy have led to the identification of predictive biomarkers that allow for
better patient selection for front line treatment. Equally important, the identification of mechanisms of acquired resistance
following front line therapy has led to the discovery of novel agents that overcome these resistance mechanisms. Improving
the efficacy of targeted therapies in the future will require expanding our understanding of resistance mechanisms, the development
of new generations of rationally designed targeted agents, and translating this information to the clinic to select patients
for appropriate therapy. (Clin Cancer Res 2009;15(24):7471–8) |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-09-1070 |